Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Beyond Traditional Structure-Based Drug Design: The Role of Iron Complexation, Strain, and Water in the Binding of Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylase 2.

Bembenek SD, Venkatesan H, Peltier HM, Rosen MD, Barrett TD, Kanelakis KC, Palomino HL, Brondstetter TI, Mirzadegan T, Rabinowitz MH.

ACS Omega. 2019 Apr 30;4(4):6703-6708. doi: 10.1021/acsomega.9b00199. Epub 2019 Apr 12.

2.

3-Substituted Quinolines as RORγt Inverse Agonists.

Tanis VM, Venkatesan H, Cummings MD, Albers M, Kent Barbay J, Herman K, Kummer DA, Milligan C, Nelen MI, Nishimura R, Schlueter T, Scott B, Spurlino J, Wolin R, Woods C, Xue X, Edwards JP, Fourie AM, Leonard K.

Bioorg Med Chem Lett. 2019 Jun 15;29(12):1463-1470. doi: 10.1016/j.bmcl.2019.04.021. Epub 2019 Apr 12.

PMID:
31010722
3.

Bioinspired Fabrication of Polyurethane/Regenerated Silk Fibroin Composite Fibres with Tubuliform Silk-Like Flat Stress⁻Strain Behaviour.

Venkatesan H, Hu J, Chen J.

Polymers (Basel). 2018 Mar 19;10(3). pii: E333. doi: 10.3390/polym10030333.

4.

6-Substituted quinolines as RORγt inverse agonists.

Barbay JK, Cummings MD, Abad M, Castro G, Kreutter KD, Kummer DA, Maharoof U, Milligan C, Nishimura R, Pierce J, Schalk-Hihi C, Spurlino J, Tanis VM, Urbanski M, Venkatesan H, Wang A, Woods C, Wolin R, Xue X, Edwards JP, Fourie AM, Leonard K.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5277-5283. doi: 10.1016/j.bmcl.2017.10.027. Epub 2017 Oct 16.

PMID:
29079472
5.

Data set for extraction and transesterification of bio-oil from Stoechospermum marginatum, a brown marine algae.

Venkatesan H, Godwin JJ, Sivamani S.

Data Brief. 2017 Aug 30;14:623-628. doi: 10.1016/j.dib.2017.08.031. eCollection 2017 Oct.

6.

Identification and structure activity relationships of quinoline tertiary alcohol modulators of RORγt.

Kummer DA, Cummings MD, Abad M, Barbay J, Castro G, Wolin R, Kreutter KD, Maharoof U, Milligan C, Nishimura R, Pierce J, Schalk-Hihi C, Spurlino J, Urbanski M, Venkatesan H, Wang A, Woods C, Xue X, Edwards JP, Fourie AM, Leonard K.

Bioorg Med Chem Lett. 2017 May 1;27(9):2047-2057. doi: 10.1016/j.bmcl.2017.02.044. Epub 2017 Feb 21.

PMID:
28318945
7.

Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats.

Barrett TD, Palomino HL, Brondstetter TI, Kanelakis KC, Wu X, Yan W, Merton KP, Schoetens F, Ma JY, Skaptason J, Gao J, Tran DT, Venkatesan H, Rosen MD, Shankley NP, Rabinowitz MH.

Br J Pharmacol. 2015 Aug;172(16):4078-88. doi: 10.1111/bph.13188. Epub 2015 Jun 26.

8.

Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor.

Barrett TD, Palomino HL, Brondstetter TI, Kanelakis KC, Wu X, Haug PV, Yan W, Young A, Hua H, Hart JC, Tran DT, Venkatesan H, Rosen MD, Peltier HM, Sepassi K, Rizzolio MC, Bembenek SD, Mirzadegan T, Rabinowitz MH, Shankley NP.

Mol Pharmacol. 2011 Jun;79(6):910-20. doi: 10.1124/mol.110.070508. Epub 2011 Mar 3.

PMID:
21372172
9.

Protecting-group-free synthesis of a dual CCK1/CCK2 receptor antagonist.

Liu J, Deng X, Fitzgerald AE, Sales ZS, Venkatesan H, Mani NS.

Org Biomol Chem. 2011 Apr 21;9(8):2654-60. doi: 10.1039/c0ob01004a. Epub 2011 Mar 2.

PMID:
21365101
10.

Benzimidazole-2-pyrazole HIF Prolyl 4-Hydroxylase Inhibitors as Oral Erythropoietin Secretagogues.

Rosen MD, Venkatesan H, Peltier HM, Bembenek SD, Kanelakis KC, Zhao LX, Leonard BE, Hocutt FM, Wu X, Palomino HL, Brondstetter TI, Haugh PV, Cagnon L, Yan W, Liotta LA, Young A, Mirzadegan T, Shankley NP, Barrett TD, Rabinowitz MH.

ACS Med Chem Lett. 2010 Oct 5;1(9):526-9. doi: 10.1021/ml100198y. eCollection 2010 Dec 9.

11.

A one-step synthesis of 2,4-unsubstituted quinoline-3-carboxylic acid esters from o-nitrobenzaldehydes.

Venkatesan H, Hocutt FM, Jones TK, Rabinowitz MH.

J Org Chem. 2010 May 21;75(10):3488-91. doi: 10.1021/jo100392x.

PMID:
20420395
12.

Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacy.

Pippel M, Boyce K, Venkatesan H, Phuong VK, Yan W, Barrett TD, Lagaud G, Li L, Morton MF, Prendergast C, Wu X, Shankley NP, Rabinowitz MH.

Bioorg Med Chem Lett. 2009 Nov 15;19(22):6376-8. doi: 10.1016/j.bmcl.2009.09.065. Epub 2009 Sep 23.

PMID:
19815410
13.

Characterization of a robust enzymatic assay for inhibitors of 2-oxoglutarate-dependent hydroxylases.

Kanelakis KC, Palomino HL, Li L, Wu J, Yan W, Rosen MD, Rizzolio MC, Trivedi M, Morton MF, Yang Y, Venkatesan H, Rabinowitz MH, Shankley NP, Barrett TD.

J Biomol Screen. 2009 Jul;14(6):627-35. doi: 10.1177/1087057109333976. Epub 2009 Jun 4.

PMID:
19498081
14.

Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.

Wiener JJ, Gomez L, Venkatesan H, Santillán A Jr, Allison BD, Schwarz KL, Shinde S, Tang L, Hack MD, Morrow BJ, Motley ST, Goldschmidt RM, Shaw KJ, Jones TK, Grice CA.

Bioorg Med Chem Lett. 2007 May 15;17(10):2718-22. Epub 2007 Mar 6.

PMID:
17382544
15.

Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR analysis.

Gomez L, Hack MD, Wu J, Wiener JJ, Venkatesan H, Santillán A Jr, Pippel DJ, Mani N, Morrow BJ, Motley ST, Shaw KJ, Wolin R, Grice CA, Jones TK.

Bioorg Med Chem Lett. 2007 May 15;17(10):2723-7. Epub 2007 Mar 6.

PMID:
17368897
16.

Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists.

Allison BD, Phuong VK, McAtee LC, Rosen M, Morton M, Prendergast C, Barrett T, Lagaud G, Freedman J, Li L, Wu X, Venkatesan H, Pippel M, Woods C, Rizzolio MC, Hack M, Hoey K, Deng X, King C, Shankley NP, Rabinowitz MH.

J Med Chem. 2006 Oct 19;49(21):6371-90.

PMID:
17034143
17.

Identification of novel inhibitors of bacterial translation elongation factors.

Jayasekera MM, Onheiber K, Keith J, Venkatesan H, Santillan A, Stocking EM, Tang L, Miller J, Gomez L, Rhead B, Delcamp T, Huang S, Wolin R, Bobkova EV, Shaw KJ.

Antimicrob Agents Chemother. 2005 Jan;49(1):131-6.

18.

Novel glycine transporter type-2 reuptake inhibitors. Part 2: beta- and gamma-amino acid derivatives.

Wolin RL, Santillán A Jr, Barclay T, Tang L, Venkatesan H, Wilson S, Lee DH, Lovenberg TW.

Bioorg Med Chem. 2004 Aug 15;12(16):4493-509.

PMID:
15265499
19.

Novel glycine transporter type-2 reuptake inhibitors. Part 1: alpha-amino acid derivatives.

Wolin RL, Venkatesan H, Tang L, Santillán A Jr, Barclay T, Wilson S, Lee DH, Lovenberg TW.

Bioorg Med Chem. 2004 Aug 15;12(16):4477-92.

PMID:
15265498
20.

Total synthesis of SR 121463 A, a highly potent and selective vasopressin v(2) receptor antagonist.

Venkatesan H, Davis MC, Altas Y, Snyder JP, Liotta DC.

J Org Chem. 2001 Jun 1;66(11):3653-61.

PMID:
11374981
21.

Supplemental Content

Loading ...
Support Center